



Evidence reviews

Evidence review

Published: 11 May 2023

www.nice.org.uk

Evidence for the 2023 recommendations can be found in the <u>evidence review on glucose</u> <u>lowering agents for managing blood glucose levels in children and young people with type 2 diabetes.</u>

Evidence for the 2022 recommendations can be found in the <u>evidence reviews on</u> <u>continuous glucose monitoring in children and young people with type 1 diabetes</u> and <u>periodontal treatment to improve diabetic control in children and young people with type 1</u> or type 2 diabetes.

Evidence for the 2020 recommendations can be found in the <u>evidence review on fluid</u> therapy for the management of diabetic ketoacidosis.

In 2018 we reviewed the evidence for SGLT2 inhibitors and GLP-1 mimetics, and made no new recommendations. See the <u>evidence review on SGLT2 inhibitors and GLP-1 mimetics</u> <u>for more information</u>.

Evidence for the 2015 recommendations can be found in the 2015 full guideline on type 1 and type 2 diabetes in children and young people, and supporting appendices:

- Full guideline
- Appendices A-N
- Appendix I